| Literature DB >> 30073814 |
Jeong Yoon Jang1, Sahmin Lee2, Dae Hee Kim2, Jong Min Song2, Duk Hyun Kang2, Jae Kwan Song3.
Abstract
BACKGROUND AND OBJECTIVES: The clinical characteristics of patients with diastolic dysfunction characterized by a relaxation abnormality with possible elevated filling pressure is remain to be determined. We sought to test whether diastolic stress echocardiography (DSE) is useful for characterization of these patients.Entities:
Keywords: Diastole; Doppler echocardiography; Exercise
Year: 2018 PMID: 30073814 PMCID: PMC6072668 DOI: 10.4070/kcj.2018.0046
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
Baseline characteristics of participants
| Demographics | Values | |
|---|---|---|
| Age (years) | 65±7 | |
| Male | 58 (48) | |
| Body surface area (m2) | 1.67±0.16 | |
| Comorbidity | ||
| Hypertension | 75 (63) | |
| Diabetes mellitus | 32 (27) | |
| Chronic lung disease | 2 (2) | |
| Coronary artery disease* | 26 (22) | |
| NYHA FC III | 1 (1) | |
| Medication | ||
| Calcium channel blocker | 41 (34) | |
| Beta-blocker | 25 (21) | |
| Diuretics | 12 (10) | |
| ACE inhibitor or ARB | 33 (28) | |
| Statin | 31 (26) | |
| LV function parameters | ||
| LV end systolic diameter (mm) | 29±5 | |
| LV end diastolic diameter (mm) | 48±4 | |
| LV ejection fraction (%) | 63±6 | |
| LA diameter (mm) | 37±5 | |
| LA volume index (mL/m2) | 36.6±10.8 | |
Data are shown as mean±standard deviation or number (%).
ACE inhibitor = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; LA = left atrial; LV = left ventricular; NYHA FC = New York Heart Association Functional Class.
*1) minimal or mild (about 50%) coronary artery stenosis on coronary angiography without regional wall motion abnormality in baseline echocardiography (N=22), 2) history of coronary intervention (N=3) or coronary bypass graft surgery (N=1) with evidence of patent stents or grafts.
Hemodynamic variables at each stage of the diastolic stress test
| Variables | Supine | 25 W exercise | 50 W exercise |
|---|---|---|---|
| Systolic blood pressure (mmHg) | 137±14 | 156±19* | 162±22†,§ |
| Diastolic blood pressure (mmHg) | 82±10 | 90±14* | 89±16§ |
| Pulse rate (beat/minute) | 68±11 | 93±12* | 104±17†,§ |
| Saturation (%) | 97±1 | 97±2 | 96±2§ |
| E (cm/s) | 61.2±11.0 | 101±17.4* | 115.4±21.0†,§ |
| A (cm/s) | 84.4±12.3 | 106.1±18.8* | 115.7±24.0†,§ |
| E/A | 0.73±0.12 | 0.97±0.18* | 1.03±0.22†,§ |
| e′ (cm/s) | 5.1±1.0 | 7.5±1.5* | 8.2±1.9†,§ |
| a′ (cm/s) | 9.3±1.4 | 12.6±2.5* | 13.8±2.9†,§ |
| E/e′ | 12.0±1.39 | 13.61±2.52* | 14.60±3.40†,§ |
| TR peak velocity (m/s) | 2.3±0.2 | 2.9±0.3* | 3.1±0.4†,§ |
| sPAP (mmHg) | 26.2±4.3 | 44.1±7.8* | 50.0±10.3†,§ |
TR = tricuspid regurgitation; sPAP = systolic pulmonary artery pressure; W = watts.
*p<0.001 between rest and 25 W; †p<0.001 between 25 and 50 W; §p<0.001 between rest and 50 W.
Figure 1Representative Doppler tracings of patients with impaired relaxation and possibly hLVFP who showed (A) no significant change, (B) hLVFP without pulmonary hypertension, (C) pulmonary hypertension without hLVFP and (D) pulmonary hypertension with hLVFP during diastolic stress echocardiography.
hLVFP = high left ventricular filling pressure; TR = tricuspid regurgitation; W = watts.
Baseline clinical variables according to the patterns of hemodynamic response during the diastolic stress test
| Variables | No change (group 1, n=33) | hLVFP only (group 2, n=22) | EiPH without hLVFP (group 3, n=40) | EiPH with hLVFP (group 4, n=25) | p value | |
|---|---|---|---|---|---|---|
| Age (years) | 62±7 | 62±7 | 66±6 | 68±8 | 0.003 | |
| Male | 19 (58) | 9 (41) | 17 (43) | 13 (52) | 0.51 | |
| Body surface area (m2) | 1.67±0.16 | 1.69±0.18 | 1.65±0.16 | 1.66±0.15 | 0.82 | |
| Comorbidity | ||||||
| Hypertension | 16 (48) | 15 (68) | 30 (75) | 14 (56) | 0.13 | |
| Diabetes mellitus | 5 (15) | 7 (32) | 12 (30) | 8 (32) | 0.41 | |
| Chronic lung disease | 0 (0) | 0 (0) | 1 (3) | 1 (4) | 0.59 | |
| Coronary artery disease | 11 (33) | 4 (18) | 8 (20) | 4 (16) | 0.54 | |
| NYHA FC II or III | 6 (3) | 9 (41) | 10 (25) | 11 (4) | 0.10 | |
| Medication | ||||||
| Calcium channel blocker | 10 (30) | 7 (32) | 18 (45) | 9 (36) | 0.29 | |
| Beta-blocker | 5 (15) | 4 (18) | 8 (20) | 8 (32) | 0.44 | |
| Diuretics | 4 (12) | 2 (9) | 6 (15) | 2 (8) | 0.70 | |
| ACE inhibitor or ARB | 10 (30) | 7 (32) | 11 (28) | 5 (20) | 0.74 | |
| Statin | 6 (18) | 5 (23) | 14 (35) | 6 (24) | 0.29 | |
| Systolic blood pressure (mmHg) | 136±11 | 135±15 | 142±13 | 133±17 | 0.07 | |
| Diastolic blood pressure (mmHg) | 82±8 | 80±10 | 87±10 | 78±8 | 0.003 | |
| Pulse rate (beat/minute) | 70±12 | 68±9 | 67±10 | 66±11 | 0.46 | |
| Saturation (%) | 97±1 | 97±1 | 97±1 | 97±1 | 0.81 | |
| LV systolic dimension (mm) | 29±5 | 28±6 | 29±6 | 29±4 | 0.90 | |
| LV diastolic dimension (mm) | 47±4 | 49±4 | 48±5 | 48±5 | 0.49 | |
| LA volume index (mL/m2) | 33.2±10.4 | 36.3±12.6 | 37.9±10.1 | 39.0±10.1 | 0.17 | |
| LV end-systolic volume (mL) | 34±12 | 33±13 | 35±15 | 34±9 | 0.97 | |
| LV end-diastolic volume (mL) | 88±25 | 89±30 | 91±24 | 95±29 | 0.77 | |
| LV ejection fraction (%) | 61±4 | 63±5 | 63±7 | 64±5 | 0.37 | |
| E (cm/s) | 69.9±15.4 | 72.9±12.6 | 67.5±13.3 | 71.3±13.6 | 0.47 | |
| A (cm/s) | 80.5±11.1 | 87.9±13.5 | 82.8±16.2 | 87.8±15.8 | 0.14 | |
| E/A | 0.87±0.15 | 0.83±0.09 | 0.84±0.19 | 0.84±0.22 | 0.83 | |
| e′ (cm/s) | 5.9±1.0 | 5.9±1.0 | 5.6±1.1 | 5.7±1.0 | 0.58 | |
| a′ (cm/s) | 9.4±1.5 | 9.5±2.3 | 9.1±1.4 | 8.7±1.2 | 0.25 | |
| E/e′ | 11.88±1.51 | 12.42±1.37 | 12.12±1.43 | 12.60±1.32 | 0.19 | |
| sPAP (mmHg) | 25±5 | 25±5 | 29±4 | 28±4 | <0.001 | |
Data are shown as mean±standard deviation or number (%).
ACE inhibitor = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; LA = left atrial; LV = left ventricular; NYHA FC = New York Heart Association Functional Classification; sPAP = systolic pulmonary artery pressure.
Hemodynamic changes during diastolic stress test in each group
| Groups | No change (group 1, n=33) | hLVFP only (group 2, n=22) | EiPH without hLFP (group 3, n=40) | EiPH with hLVFP (group 4, n=25) | p value† | |
|---|---|---|---|---|---|---|
| Supine | Systolic blood pressure (mmHg) | 136±11 | 135±15 | 143±13 | 133±17 | 0.07 |
| Diastolic blood pressure (mmHg) | 82±8 | 80±10 | 87±10 | 78±8 | 0.003 | |
| Pulse rate (beat/minute) | 70±12 | 68±9 | 67±10 | 66±11 | 0.46 | |
| Saturation (%) | 97±1 | 97±1 | 97±1 | 97±1 | 0.81 | |
| E (cm/s) | 69.9±15.4 | 72.9±12.6 | 67.5±13.3 | 71.3±13.6 | 0.47 | |
| A (cm/s) | 80.5±11.1 | 87.9±13.5 | 82.8±16.2 | 87.8±15.8 | 0.14 | |
| E/A | 0.87±0.15 | 0.83±0.09 | 0.84±0.19 | 0.84±0.22 | 0.83 | |
| e′ (cm/s) | 5.9±1.0 | 5.9±1.0 | 5.6±1.1 | 5.7±1.0 | 0.58 | |
| a′ (cm/s) | 9.4±1.5 | 9.5±2.3 | 9.1±1.4 | 8.7±1.2 | 0.25 | |
| E/e′ | 11.88±1.51 | 12.42±1.37 | 12.12±1.43 | 12.60±1.32 | 0.19 | |
| TR peak velocity (m/s) | 2.2±0.3 | 2.2±0.3 | 2.5±0.2 | 2.4±0.2 | <0.001 | |
| sPAP (mmHg) | 25±5 | 25±5 | 29±4 | 28±4 | <0.001 | |
| 25 W | Systolic blood pressure (mmHg) | 153±17* | 156±22* | 162±17* | 151±23* | 0.16 |
| Diastolic blood pressure (mmHg) | 90±12* | 89±13* | 93±12* | 85±18* | 0.19 | |
| Pulse rate (beat/minute) | 92±12* | 92±14* | 95±12* | 93±12* | 0.75 | |
| Saturation (%) | 97±3 | 97±1 | 97±3 | 97±2 | 0.90 | |
| E (cm/s) | 96.6±17.5* | 110.5±21.1* | 95.6±15.5* | 105.2±11.3* | 0.002 | |
| A (cm/s) | 104.4±16.1* | 109.0±22.6* | 105.3±20.5* | 106.9±16.1* | 0.83 | |
| E/A | 0.94±0.18* | 1.03±0.19* | 0.93±0.17* | 1.00±0.16* | 0.07 | |
| e′ (cm/s) | 7.9±1.7* | 7.4±1.6* | 7.7±1.3* | 6.9±1.0* | 0.06 | |
| a′ (cm/s) | 13.1±2.6* | 12.2±2.7* | 12.7±2.3* | 11.8±2.4* | 0.20 | |
| E/e′ | 12.36±1.72* | 15.21±2.42* | 12.64±2.01 | 15.42±2.53* | <0.001 | |
| TR peak velocity (m/s) | 2.6±0.3* | 2.6±0.3* | 3.1±0.2* | 3.0±0.3* | <0.001 | |
| sPAP (mmHg) | 38±6* | 38±5* | 50±6* | 48±6* | <0.001 | |
| 50 W | Systolic blood pressure (mmHg) | 159±19*,§ | 163±25* | 168±22* | 156±24* | 0.14 |
| Diastolic blood pressure (mmHg) | 91±15* | 87±17* | 92±14* | 86±19* | 0.41 | |
| Pulse rate (beat/minute) | 103±17*,§ | 104±16*,§ | 109±19*,§ | 101±12*,§ | 0.27 | |
| Saturation (%) | 97±2 | 96±2 | 96±2 | 97±2* | 0.96 | |
| E (cm/s) | 109.8±21.2*,§ | 123.4±22.4*,§ | 108.4±17.7*,§ | 126.9±17.6*,§ | <0.001 | |
| A (cm/s) | 114.0±18.8*,§ | 119.7±30.4*,§ | 114.4±26.4*,§ | 116.5±20.6*,§ | 0.82 | |
| E/A | 0.97±0.18* | 1.08±0.25* | 0.98±0.22*,§ | 1.11±0.22*,§ | 0.031 | |
| e′ (cm/s) | 9.0±1.9*,§ | 7.2±1.5* | 8.8±1.9*,§ | 7.0±0.9* | <0.001 | |
| a′ (cm/s) | 14.6±3.1*,§ | 13.3±2.5*,§ | 14.2±3.2*,§ | 12.8±2.0* | 0.07 | |
| E/e′ | 12.42±1.87 | 17.36±2.03*,§ | 12.49±1.66 | 18.42±2.90*,§ | <0.001 | |
| TR peak velocity (m/s) | 2.7±0.3*,§ | 2.8±0.3*,§ | 3.4±0.2*,§ | 3.5±0.2*,§ | <0.001 | |
| sPAP (mmHg) | 41±6*,§ | 42±6*,§ | 57±6*,§ | 59±7*,§ | <0.001 | |
Data are shown as mean±standard deviation or number (%).
sPAP = systolic pulmonary artery pressure; TR = tricuspid regurgitation; W = watts.
*p<0.05 compared with supine; †comparison among groups; §p<0.05 between 25 and 50 W.